AEterna's CEO, CBO resign

Fri, 11 Apr 2008 06:59:56 -0400

David Mazzo announced that he's resigning from AEterna Zentaris after exactly one year as CEO. Reasons for the move were not disclosed. Board chairman Juergen Ernst will serve as interim President and CEO until a replacement can be found. Senior VP and chief business officer Ellen McDonald also resigned--no word yet on who will replace her. Both resignations take effect immediately.

Additionally, the company said that it will look to sell additional non-core assets as a source of non-dilutive funding.

- read the release

ALSO: Pharmacopeia's CEO Leslie Browne has resigned in order to pursue other interests. His resignation was effective April 9. Release

Related Articles:
AEterna files iNDA. Aeterna report
AEterna Zentaris announces ZEN-012 data. AEterna report
AEterna regains rights to Cetrorelix. AEterna report

AEterna gets its ducks in a row

Wed, 03 Oct 2007 06:59:54 -0400

Executives at AEterna Zentaris have taken a good, long look at the company's pipeline and operations and have identified a number of changes that will take place.

Cetrorelix, currently in a Phase III program for benign prostatic hyperplasia, is AEterna's highest priority. The company also plans to move into Phase IIb trials for the endometriosis indication of the drug.
AEZS-108, a cytotoxic conjugate, is AEterna's highest earlier-stage priority, and will therefore. Phase II trials of the drug both endometrial and ovarian cancers will get underway this year. The company also prioritized early-stage drug candidates.
All projects will be developed internally through proof-of-concept in man, but non AEterna will look to unload non-core assets.
Asia (especially Japan) remains a market of interest for AEZS.

- see this release from AEterna

Related Articles:
AEterna files iNDA. Report
AEterna Zentaris announces ZEN-012 data. Report
AEterna regains rights to Cetrorelix. Report